We at the Blue Buffalo Company have just learned that American Nutrition Inc. (ANI), the manufacturer of all our cans and biscuits, has been adding rice protein concentrate to our can formulas without our knowledge and without our approval.
Solvay announced that its dossier for intravenous tedisamil (intended brand name: PULZIUM? IV), a new chemical entity coming from Solvay Pharmaceuticals R&D laboratories, has been filed for approval by the US Food and Drug Administration (FDA) as well as by the authorities of European U nion countries.
Because of the canned pet food recall initiated by American Nutrition Inc., Diamond Pet Foods has announced it is withdrawing a limited number of canned products manufactured by American Nutrition.
After three months in preview mode, Revolution Health has formally launched RevolutionHealth.com, a comprehensive health and medical information site, specially designed with the family’s Chief Health Officer – busy moms and other caregivers – in mind.
The “morning after pill” may be a good option for individual women in crisis, but advance access to emergency contraception is no antidote for the national problem of unintended pregnancy.
Adding the once daily, investigational medication REQUIP(R) (ropinirole HCl) XL 24-Hour(TM) Extended-Release Tablets to Parkinson’s patients’ existing levodopa (L-dopa) therapy significantly reduced ‘off’ time, allowing patients to continue their daily activities for a longer period of time.
A WHO background document will be used to help guide discussions and stir debate. The paper profiles eight issues linked to international health security, together with key points to focus the debate:
The U.S. Food & Drug Administration (FDA) is launching a special Web page to warn consumers about the dangers of buying isotretinoin (Accutane) online.
A common asthma inhaler powered by a new propellant is safe and effective but could come at nearly triple the cost to consumers until a generic version hits the market, according to a review in today’s (March 29) New England Journal of Medicine.
Schering-Plough Corporation (NYSE: SGP) announced that it has entered into an agreement with Merck & Co., Inc. to commence development of an ezetimibe and atorvastatin combination product.